Non-small cell lung cancer – Current drug regimens for NSCLC
December 20th, 2006
Surgery remains confined to localized NSCLC patients and the majority of patients are diagnosed in advanced stages of the disease, where platinum analogue-based pharmacotherapy is the mainstay of treatment. The introduction of third-generation cytotoxics has raised the hope of significantly improving efficacy, but prognosis is still poor, and the survival rate has remained relatively stagnant.